Medicare AdvantageCoverageMedium impact
MA08.174, Secukinumab (Cosentyx®) for Intravenous Use
Independence Blue Cross·Rheumatology, Dermatology, Gastroenterology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.174 for Secukinumab (Cosentyx®) intravenous use has been reissued and will become effective May 28, 2025. This policy update may affect coverage criteria or billing requirements for this specialty biologic medication used primarily in rheumatology and dermatology.
Action Required
By May 28, 2025: Billing team should review the updated policy MA08.174 for Secukinumab (Cosentyx®) intravenous use to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Medicare Advantage patients. Contact the payer or access the full policy document to determine specific billing impacts.